ArticleScientific reports2018
Complete genome analysis of a Siphoviridae phage TSK1 showing biofilm removal potential against Klebsiella pneumoniae.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 88 citations in OpenAlex.
- Harnessing lytic phages for biofilm control in carbapenem-resistantMicrobiology spectrum · 2026Article
- Antimicrobial Potential and Genomic Insights of Novel Klebsiella Phage SBP against K-112 Serotype.Current microbiology · 2026Article
- A comprehensive analysis of the kinetics of infection of lytic bacteriophages specific to the ESKAPE and critical pathogens.World journal of microbiology & biotechnology · 2026Review
- Isolation, characterization, and genomic analysis of novel bacteriophage AEV23 against multidrug-resistant Klebsiella pneumoniae isolated from Cystic Fibrosis patients.BMC microbiology · 2026Article
- Genomic and functional characterization of a novel lytic phage vB-AbaM-fThrA with anti-biofilm activity against CR-MDR Acinetobacter baumannii.BMC microbiology · 2025Article
- Genomic and physiochemical characterization of two lysogenic bacteriophages, ΦCP5(17) and ΦCP17(i), infecting Clostridium perfringens.Archives of virology · 2025Article
- Phage therapy for antimicrobial-resistant Klebsiella spp. infections: a review of mechanisms, synergies, and clinical potential.Archives of microbiology · 2025Review
- A case report of bacteriophage therapy for the treatment of lung infection due to carbapenem-resistant Pseudomonas aeruginosa.Scientific reports · 2025Article
- Bacteriophage-Based Approach Against Biofilm Infections Associated with Medical Devices: A Narrative Review of ESKAPE Pathogens.International journal of molecular sciences · 2025Review
- Combined Forces Against Bacteria: Phages and Antibiotics.Health science reports · 2025Article
- Unseen Enemy: Mechanisms of Multidrug Antimicrobial Resistance in Gram-Negative ESKAPE Pathogens.Antibiotics (Basel, Switzerland) · 2025Review
- Bacteriophage therapy: a possible alternative therapy against antibiotic-resistant strains ofFrontiers in microbiology · 2025Review
- Isolation, characterization and therapeutic evaluation of phage HHU1 against K2Frontiers in cellular and infection microbiology · 2025Article
- DeepPBI-KG: a deep learning method for the prediction of phage-bacteria interactions based on key genes.Briefings in bioinformatics · 2024Article
- A NovelCurrent issues in molecular biology · 2024Article
- A NewPharmaceutics · 2024Article
- Biofilm inhibition/eradication: exploring strategies and confronting challenges in combatting biofilm.Archives of microbiology · 2024Review
- Effect of Bacteriophages against Biofilms ofMicroorganisms · 2024Article
- Active prophages in coral-associated Halomonas capable of lateral transduction.The ISME journal · 2024Article
- Isolation and characterization of two novel bacteriophages against carbapenem-resistantFrontiers in cellular and infection microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Multidrug-resistant Klebsiella pneumoniae is a nosocomial pathogen, produces septicemia, pneumonia and UTI. Excessive use of antibiotics contributes towards emergence of multidrug-resistance. Bacteriophage-therapy is a potential substitute of antibiotics with many advantages. In this investigation, microbiological and genome characterization of TSK1 bacteriophage and its biofilm elimination capability are presented. TSK1 showed narrow host range and highest stability at pH 7 and 37 °C. TSK1 reduced the growth of K. pneumoniae during the initial 14 hours of infection. Post-treatment with TSK1 against different age K. pneumoniae biofilms reduced 85-100% biomass. Pre-treatment of TSK1 bacteriophage against the biofilm of Klebsiella pneumoniae reduced > 99% biomass in initial 24 hr of incubation. The genome of TSK1 phage comprised 49,836 base pairs with GC composition of 50.44%. Total seventy-five open reading frames (ORFs) were predicted, 25 showed homology with known functional proteins, while 50 were called hypothetical, as no homologs with proved function exists in the genome databases. Blast and phylogenetic analysis put it in the Kp36 virus genus of family Siphoviridae. Proposed packaging strategy of TSK1 bacteriophage genome is headful packaging using the pac sites. The potential of TSK1 bacteriophage could be used to reduce the bacterial load and biofilm in clinical and non-clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.